Comparison 1. Antiplatelet drug versus control in acute presumed ischaemic stroke.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death or dependence at end of follow‐up	4	41291	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.91, 0.99]
1.1 Aspirin versus control	4	41291	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.91, 0.99]
2 Deaths from all causes during treatment period	8	41483	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.92 [0.85, 1.00]
2.1 Aspirin versus control	4	41291	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.92 [0.85, 1.00]
2.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.47 [0.43, 4.99]
2.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.12 [0.01, 1.20]
3 Deaths from all causes during follow‐up	8	41483	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.92 [0.87, 0.98]
3.1 Aspirin versus control	4	41291	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.92 [0.87, 0.98]
3.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.47 [0.43, 4.99]
3.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.12 [0.02, 0.88]
4 Deep venous thrombosis during treatment period	2	133	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.78 [0.36, 1.67]
4.1 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.35 [0.13, 0.95]
4.2 Ticlopidine versus control	1	53	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.37 [0.72, 7.73]
5 Pulmonary embolism during treatment period	7	41042	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.71 [0.53, 0.96]
5.1 Aspirin versus control	3	40850	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.71 [0.53, 0.97]
5.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	7.39 [0.15, 372.38]
5.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.13 [0.01, 2.06]
6 Recurrent ischaemic/unknown stroke during treatment period	7	41042	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.77 [0.69, 0.87]
6.1 Aspirin versus control	3	40850	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.77 [0.69, 0.87]
6.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Symptomatic intracranial haemorrhage during treatment period	7	41042	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.23 [1.00, 1.50]
7.1 Aspirin versus control	3	40850	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.22 [1.00, 1.50]
7.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.0 [0.14, 7.38]
7.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.70 [0.36, 20.26]
8 Any recurrent stroke/intracranial haemorrhage during treatment period	7	41042	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.88 [0.79, 0.97]
8.1 Aspirin versus control	3	40850	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.87 [0.79, 0.97]
8.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.0 [0.14, 7.38]
8.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.70 [0.36, 20.26]
9 Major extracranial haemorrhage during treatment period	7	41042	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.69 [1.35, 2.11]
9.1 Aspirin versus control	3	40850	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.69 [1.35, 2.11]
9.2 Aspirin plus dipyridamole versus control	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
9.3 Ticlopidine versus control	3	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Complete recovery from stroke (post hoc)	2	40541	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.06 [1.01, 1.11]
10.1 Aspirin versus control	2	40541	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.06 [1.01, 1.11]